atazanavir sulfate and cobicistat
atazanavir sulfate and cobicistat · ATAZANAVIR SULFATE 300 mg/1; COBICISTAT 150 mg/1 · Tablet · Patheon Inc.
NDC 66406-0289-00 · 9291 TABLET in 1 CONTAINER · DRUG FOR FURTHER PROCESSING · View full market →
Bulk ingredient — not a finished product
This NDC is a raw material (drug for further processing) sold to drug manufacturers or compounders, not a product pharmacies dispense. Retail pricing, TE codes, fragility scores, and shortage reports don't apply to bulk listings — those attach to finished products made from this ingredient.
Medicare Part D
This is a bulk ingredient, not a dispensable product — it is a raw material sold to manufacturers and compounders, so no plan prices it.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Regulatory
- Application
- —
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- —
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of atazanavir sulfate and cobicistat (Tablet)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Patheon Inc. | ATAZANAVIR SULFATE 300 mg/1; COBICISTAT 150 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "atazanavir sulfate and cobicistat — NDC 66406-0289-00," retrieved September 3, 2026, https://drugdashboards.com/drug/66406028900.
Free to cite with attribution — see how the data is put together.